Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 15.90
- Piotroski Score 2.00
- Grade Buy
- Symbol (AKRO)
- Company Akero Therapeutics, Inc.
- Price $26.74
- Changes Percentage (-0.11%)
- Change -$0.03
- Day Low $26.52
- Day High $27.65
- Year High $53.00
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/10/2024
- Fiscal Year End N/A
- Average Stock Price Target $45.00
- High Stock Price Target $56.00
- Low Stock Price Target $38.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.24
- Trailing P/E Ratio -7.1
- Forward P/E Ratio -7.1
- P/E Growth -7.1
- Net Income $-151,759,000
Income Statement
Quarterly
Annual
Latest News of AKRO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Akron takes a break from power-conference opponents to beat FCS foe Colgate 31-20
Akron defeated Colgate 31-20, with Ben Finley throwing for 358 yards and four touchdowns. Bobby Golden and Adrian Norton each had 100+ yards receiving and a touchdown. Akron avoided a 0-3 start, while...
By AP NEWS | 2 days ago -
Akero Therapeutics, Inc. (AKRO): This Small-Cap Healthcare Stock Is A Good Buy Right Now
A list of top small-cap healthcare stocks includes Akero Therapeutics, Inc. (NASDAQ: AKRO), focusing on innovative treatments for metabolic diseases. The company's lead product candidate, EFX, shows p...
By Yahoo! Finance | 1 week ago -
How good was Will Howard's Ohio State debut? What I saw from the QB against Akron
Howard showcased his skills in Ohio State's new offense, displaying mobility, accuracy, and red zone efficiency. His performance against Akron revealed his adaptability and potential impact on the tea...
By The New York Times | 2 weeks ago
